Dietary Intake by Patients Taking GLP-1 and Dual GIP/GLP-1 Receptor Agonists

Author(s): Sandra Christensen, MSN, ARNP, FNP-BC, MFOMA, FAANP
                   Katie Robinson, PhD, MPH, RD, LD, CNSC
                   Sara Thomas, PhD, RD
                   Dominique Williams, MD, MPH, FOMA, DIPL ABOM

Abstract:

Due to the high efficacy of glucagon-like peptide receptor agonists (GLP-1RAs) and dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) for weight reduction and glycemic control, there is increased utilization for patients with obesity and/or T2DM. Yet, the impact of these medications on dietary intake is less understood. This narrative literature review summarizes clinical studies quantifying and characterizing dietary intake in people with obesity and/or T2DM using GLP-1 or GIP/GLP-1 RA.